Liaw Yun-fan

Q: What Schools Are Affiliated With Liaw Yun-fan

Liaw Yun-fan is affiliated with the following schools: University of Southern California, National Taiwan University, Chang Gung University

Liaw Yun-fan's AcademicInfluence.com Rankings

Liaw Yun-fan

Philosophy

#3682

World Rank

#5902

Historical Rank

Logic

#1327

World Rank

#2049

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Liaw Yun-fan's Degrees

Doctorate Medicine National Taiwan University
PhD Medical Science National Taiwan University

Why Is Liaw Yun-fan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Liaw Yun-fan is a Taiwanese hepatologist. He attended Hsinchu Senior High School and earned his medical degree from the College of Medicine at National Taiwan University in 1967. Liaw completed his residency in internal medicine at National Taiwan University, where he became chief resident. After Liaw's residency, he began teaching as a clinical assistant professor at the National Defense Medical Center. He joined the Chang Gung University Medical College faculty in 1987, having served as director of the affiliated Department of Hepato-Gastroenterology and the Liver Research Unit at the Chang Gung Memorial Hospital since 1976. Liaw was named a member of the Academia Sinica in 2000. That same year, he helped compile a hepatitis B prevention guide for use across Asia after attending the International Liver Congress in Fukuoka, Japan. In 2012, Liaw was appointed distinguished chair professor, and was honored by the European Association for the Study of the Liver as the 2013 recipient of its International Recognition Award.

(See a Problem?)

Liaw Yun-fan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Lamivudine for patients with chronic hepatitis B and advanced liver disease. (2004) (2235)
Hepatitis B e antigen and the risk of hepatocellular carcinoma. (2002) (1243)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (2012) (1019)
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010) (1013)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008) (926)
Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B (2010) (870)
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. (2000) (714)
Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B (2002) (689)
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study (1988) (638)
Hepatitis B virus infection (2009) (592)
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. (2009) (570)
Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma (2008) (566)
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. (2005) (563)
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy (1999) (528)
Epidemiological characteristics and risk factors of hepatocellular carcinoma (1997) (487)
Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management (2007) (474)
Detection of type 2‐like T‐helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity (1997) (463)
Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection (1999) (458)
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. (2006) (421)
Natural history of chronic hepatitis B virus infection in taiwan: Studies of hepatitis B virus DNA in serum (1985) (404)
Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update (2005) (389)
Liver biochemical tests and dengue fever. (1992) (370)
Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. (1983) (350)
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. (2002) (326)
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. (2007) (325)
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. (1986) (323)
HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long‐term follow‐up (2007) (323)
Telbivudine versus lamivudine in patients with chronic hepatitis B. (2007) (322)
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B (2002) (317)
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease (2011) (316)
Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study (1991) (314)
Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. (1997) (306)
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B (1999) (296)
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. (2010) (292)
Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. (2004) (286)
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. (1988) (280)
Role of hepatitis C virus in dual and triple hepatitis virus infection (1995) (268)
Identity of a Novel Swine Hepatitis E Virus in Taiwan Forming a Monophyletic Group with Taiwan Isolates of Human Hepatitis E Virus (1999) (266)
Genome-wide hypomethylation in hepatocellular carcinogenesis. (2001) (261)
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. (2010) (248)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B (2008) (247)
Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. (2014) (241)
Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma (1991) (237)
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. (2004) (236)
Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy (2000) (227)
Determinants for sustained HBeAg response to lamivudine therapy (2003) (225)
Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. (2000) (225)
Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels (2013) (216)
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study (2011) (206)
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. (2009) (203)
Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. (1987) (202)
Hepatitis B virus-related cirrhosis: natural history and treatment. (2006) (202)
Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment (2009) (200)
Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients (2013) (200)
Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C (2011) (199)
Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (2000) (196)
Constitutive activation of nuclear factor κB in hepatocellular carcinoma (2000) (189)
Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. (1995) (188)
Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks (2008) (186)
Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. (2012) (183)
Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B (2018) (181)
Clinical associations between thyroid and liver diseases (1995) (179)
A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan (2006) (173)
Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: A longitudinal study (1993) (171)
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. (2012) (171)
Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. (2008) (170)
Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. (2005) (170)
Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. (2007) (170)
Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time (2009) (168)
Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B– and C–related risk (2003) (167)
Non‐surgical treatment of hepatocellular carcinoma (1997) (165)
Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti‐hepatitis B virus therapy 1 (2003) (162)
Age‐specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B (2010) (162)
Hepatitis B surface antigen seroclearance during chronic HBV infection (2010) (161)
Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. (1999) (160)
Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. (2001) (160)
Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody‐positive patients (1987) (157)
Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion (2007) (155)
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update * (2003) (154)
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. (1998) (150)
Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. (1992) (150)
Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. (1994) (149)
The Natural History of Chronic HBV Infection and Geographical Differences (2010) (146)
Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. (2000) (138)
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B (2009) (137)
Ap53genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers (1999) (136)
The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport (1990) (136)
Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. (1985) (134)
Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. (1991) (130)
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy (2006) (126)
Hepatic Injury during Propylthiouracil Therapy in Patients with Hyperthyroidism: A Cohort Study (1993) (126)
Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors (2004) (125)
The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. (2003) (123)
Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. (1994) (122)
Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. (2009) (119)
Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial (1998) (118)
Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. (2008) (117)
The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. (1994) (117)
Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. (1996) (116)
Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma (2007) (115)
Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. (1997) (113)
Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. (2005) (112)
Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study (1999) (111)
Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure (1999) (110)
Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. (2000) (110)
Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3) (2008) (110)
Bacteremia in patients with cirrhosis of the liver. (2008) (108)
Telbivudine improves renal function in patients with chronic hepatitis B. (2014) (108)
Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. (2003) (107)
Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B (2015) (106)
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study (2007) (106)
Incidence and Risk Factors of Progression to Cirrhosis in Inactive Carriers of Hepatitis B Virus (2009) (100)
Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus (1999) (98)
Impact of acute hepatitis B virus superinfection on chronic hepatitis c virus infection (2000) (97)
Low-Level Viremia and Intracellular Expression of Hepatitis B Surface Antigen (HBsAg) in HBsAg Carriers with Concurrent Hepatitis C Virus Infection (1998) (96)
Precore Stop Mutant in HBeAg-Positive Patients with Chronic Hepatitis B: Clinical Characteristics and Correlation with the Course of HBeAg-to-Anti-HBe Seroconversion (2002) (94)
Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. (1985) (92)
T‐cell–mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection (1995) (92)
Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. (2008) (89)
Age‐specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in taiwan: A comparison among asymptomatic carriers, Chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (1984) (87)
Natural history of chronic hepatitis B virus infection: An immunopathological study (1997) (86)
Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection (2010) (85)
Hepatocellular carcinoma presenting as bone metastasis (1989) (84)
High Prevalence of TT Virus Infection in Healthy Children and Adults and in Patients with Liver Disease in Taiwan (1999) (83)
Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? (2007) (83)
Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study. (1994) (82)
Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. (1995) (82)
No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations (2004) (81)
Clinical and Virological Course of Chronic Hepatitis B Virus Infection With Hepatitis C and D Virus Markers (1998) (80)
Prednisolone Priming Enhances Th1 Response and Efficacy of Subsequent Lamivudine Therapy in Patients With Chronic Hepatitis B (2000) (80)
Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. (1996) (80)
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review (2011) (80)
Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis (1987) (79)
Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. (1999) (78)
Hepatitis viruses under immunosuppressive agents (1998) (77)
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B (2012) (76)
Hepatic injury during ketoconazole therapy in patients with onychomycosis: A controlled cohort study (1997) (76)
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. (2005) (76)
The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. (1982) (76)
Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. (1993) (75)
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review (2011) (73)
White count, ph and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis (1985) (73)
Helicobacter pylori in cirrhotic patients with peptic ulcer disease: a prospective, case controlled study. (1995) (72)
Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma (2000) (71)
Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. (1994) (71)
Controlled Trial of Protease Inhibitor Gabexelate Mesilate (FOY) in the Treatment of Acute Pancreatitis (1987) (70)
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. (2006) (70)
Results of lamivudine trials in Asia. (2003) (70)
Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. (2001) (70)
Hepatitis B X-gene expression in hepatocellular carcinoma. (1992) (69)
Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. (2012) (67)
A simple noninvasive index for predicting long‐term outcome of chronic hepatitis C after interferon‐based therapy (2006) (67)
Therapy of chronic hepatitis B: current challenges and opportunities (2002) (66)
Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers (1999) (66)
Spontaneous relapse of hepatitis in inactive HBsAg carriers (2007) (65)
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial (2005) (64)
The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers (1989) (64)
Impact of therapy on the outcome of chronic hepatitis B (2013) (63)
Activation of Th1 Immunity Is a Common Immune Mechanism for the Successful Treatment of Hepatitis B and C: Tetramer Assay and Therapeutic Implications (2003) (63)
The role of laparoscopy in the evaluation of ascites of unknown origin. (1994) (62)
Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. (2007) (61)
Metastatic septic endophthalmitis in pyogenic liver abscess. (1988) (60)
Detection and partial sequence analysis ofHelicobacter pylori DNA in the bile samples (1995) (60)
Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma (2014) (59)
Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection (2008) (59)
Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. (1990) (57)
The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B (2003) (57)
New perspectives in the therapy of chronic hepatitis B (2012) (57)
Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. (2016) (56)
Influences of tobacco and alcohol use on hepatocellular carcinoma survival (2012) (55)
The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: A prospective study (1989) (55)
Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. (2010) (55)
Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination (1991) (55)
Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. (1997) (54)
Sex Difference in Chronic Hepatitis B Virus Infection: An Appraisal Based on the Status of Hepatitis B e Antigen and Antibody (2007) (54)
The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection (1997) (54)
Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without (2012) (54)
Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection (1987) (54)
Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. (2013) (52)
Characterization of a new genotype II hepatitis delta virus from Taiwan (1996) (51)
Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. (2008) (51)
HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: Its role in the pathogenesis of chronic type B hepatitis (1987) (51)
Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. (2000) (50)
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. (2016) (49)
Current therapeutic trends in therapy for chronic viral hepatitis (1997) (49)
Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study. (1990) (48)
High incidence of hepatitis C virus infection in hemodialysis patients in Taiwan. (1993) (47)
Switching to adefovir monotherapy after emergence of lamivudine‐resistant mutations in patients with liver cirrhosis (2006) (47)
Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection (2019) (47)
Membrane staining for hepatitis B surface antigen on hepatocytes: a sensitive and specific marker of active viral replication in hepatitis B. (1995) (47)
Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. (2009) (46)
Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization. (1987) (46)
Impact of therapy on the long-term outcome of chronic hepatitis B. (2013) (45)
Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic (1996) (44)
Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B (2002) (44)
Efficacy and safety of prolonged 3‐year telbivudine treatment in patients with chronic hepatitis B (2011) (44)
Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. (2004) (43)
Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift (2019) (43)
Prevalence and prognostic significance of bacterascites in cirrhosis with ascites (1995) (43)
A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices (1990) (43)
Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. (1996) (43)
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. (2019) (42)
Comparison of long‐term effects of lymphoblastoid interferon alpha and recombinant interferon alpha‐2a therapy in patients with chronic hepatitis B (2004) (42)
Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicentre study in Asia (1998) (41)
Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy (2009) (41)
Prevalence of antibodies to hepatitis C virus in the hemodialysis unit. (1991) (41)
Relative Roles of HBsAg Seroclearance and Mortality in the Decline of HBsAg Prevalence With Increasing Age (2010) (41)
Impact of hepatitis B therapy on the long‐term outcome of liver disease (2011) (41)
Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak (1986) (41)
Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis. (2008) (40)
Frequent allelic loss on chromosomes 4q and 16q associated with human hepatocellular carcinoma in Taiwan. (1998) (40)
Hepatocellular carcinoma in noncirrhotic patients. A laparoscopic study of 92 cases in Taiwan (1984) (40)
Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. (1998) (40)
69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS (2011) (40)
Seroepidemiological studies on hepatitis B and D viruses infection among five ethnic groups in southern Taiwan (1988) (39)
Jaundice after open heart surgery: a prospective study. (1984) (39)
Taiwan consensus statement on the management of chronic hepatitis B. (2019) (39)
Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. (2008) (39)
Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (2012) (39)
Somatosensory evoked potentials in hepatic encephalopathy. (1985) (38)
Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. (2009) (38)
Cellular immune responses in patients with dual infection of hepatitis B and C viruses: Dominant role of hepatitis C virus (1995) (38)
Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. (2005) (37)
Evoked potentials in liver diseases (1997) (37)
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network (2016) (37)
Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion (2012) (36)
Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection (2012) (36)
Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. (2015) (36)
The prognostic significance of bridging hepatic necrosis in chronic type B hepatitis: a histopathologic study. (2008) (36)
Hepatitis C virus infection facilitates gallstone formation (2005) (36)
Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. (2002) (36)
Management of patients with chronic hepatitis B (2002) (35)
Molecular cloning of a defective hepatitis C virus genome from the ascitic fluid of a patient with hepatocellular carcinoma. (1997) (34)
Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis B virus infection (1992) (34)
Etiology of sporadic acute viral hepatitis in Taiwan: The role of hepatitis C virus, hepatitis E virus and GB virus‐C/hepatitis G virus in an endemic area of hepatitis A and B (1999) (34)
Diagnostic Markers of Chronic Hepatitis B Infection and Disease (2010) (34)
Chronic hepatitis B: a critical appraisal of current approaches to therapy. (2006) (34)
Identification of a Hepatic Factor Capable of Supporting Hepatitis C Virus Replication in a Nonpermissive Cell Line (2001) (34)
Immunohistological study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitis. (1992) (34)
Brainstem auditory evoked potentials in hepatic encephalopathy (1986) (33)
G1 phase dependent nuclear localization of relaxed‐circular hepatitis B virus DNA and aphidicolin‐induced accumulation of covalently closed circular DNA (1998) (33)
HLA Class i antigen display on hepatocyte membrane in chronic hepatitis B virus infection: Its role in the pathogenesis of chronic type B hepatitis (1988) (33)
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. (2008) (33)
JGH and Asia–Pacific consensus on prevention and management of gastrointestinal and liver diseases (2000) (33)
Chronic hepatitis B: treatment alert (2006) (33)
The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. (1992) (32)
Hepatic tuberculosis: Comparison of miliary and local form (1995) (32)
Chronic Lobular Hepatitis: A Clinicopathological and Prognostic Study (2007) (32)
The current management of HBV drug resistance. (2005) (31)
L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. (1996) (31)
[A clinical study on pyogenic liver abscess]. (1987) (31)
Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. (2008) (31)
Rescue therapy for lamivudine‐resistant chronic hepatitis B: When and how? (2007) (30)
HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients. (2018) (30)
Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. (2010) (30)
Hemostatic effect of endoscopic local injection with hypertonic saline-epinephrine solution and pure ethanol for digestive tract bleeding. (1986) (30)
Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV (2002) (30)
Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B (2018) (30)
Amino acid substitutions in codons 9–11 of hepatitis C virus core protein lead to the synthesis of a short core protein product (2000) (30)
Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis. (1993) (30)
Correlation of mutational analysis to clinical features in Taiwanese patients with Gilbert's syndrome (2001) (29)
Chronic hepatitis B: past, present, and future. (2010) (29)
Increased Incidence of Fulminant Hepatic Failure in Previously Unrecognized HBsAg Carriers with Acute Hepatitis Independent of Etiology (2005) (29)
Studies on the composition of the mononuclear cell infiltrates in liver from patients with chronic active delta hepatitis (1989) (29)
Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: Incidence and risk factors (1996) (27)
Antisense overexpression of BMAL2 enhances cell proliferation (2003) (27)
The etiology of acute viral hepatitis in an endemic area of hepatitis A and B. (1983) (27)
Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells (2003) (27)
Cloning and characterization of the extreme 5'-terminal sequences of the RNA genomes of GB virus C/hepatitis G virus. (1997) (27)
Hepatocellular carcinoma associated with second primary malignancy. (2008) (27)
Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women (2002) (27)
Concurrent hepatitis B and C virus infection: Is hepatitis C virus stronger? (2001) (26)
Methylation at cg05575921 of a smoking-related gene (AHRR) in non-smoking Taiwanese adults residing in areas with different PM2.5 concentrations (2019) (26)
On-Treatment Outcome Prediction and Adjustment during Chronic Hepatitis B Therapy: Now and Future (2009) (26)
High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B (2004) (26)
Correlation of age with the status of hepatitis B virus replication and histological changes in chronic type B hepatitis. (2008) (25)
Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg‐Negative Chronic Hepatitis B: To Retreat or Not to Retreat (2020) (25)
Hepatitis B Virus in Human Diseases (2016) (25)
Simultaneous acute hepatitis B virus and hepatitis C virus infection leading to fulminant hepatitis and subsequent chronic hepatitis C. (1995) (24)
Eight‐year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: Role of viral infection (2002) (24)
Short-Term Lamivudine Therapy in Hbeag-Negative Chronic Active Hepatitis B in Taiwan (2006) (24)
Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B. (1998) (24)
Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon γ signalling pathway (2010) (24)
Resolution of liver abscesses: comparison of pyogenic and amebic liver abscesses. (1989) (24)
Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. (2002) (24)
Gene gun bombardment with DNA-coated gold particles is a potential alternative to hydrodynamics-based transfection for delivering genes into superficial hepatocytes. (2008) (24)
Granulomatous hepatitis associated with scrub typhus (1995) (24)
Acute exacerbation and superinfection in patients with chronic viral hepatitis. (1995) (23)
Thymalfasin (thymosin‐alpha 1) therapy in patients with chronic hepatitis B (2004) (23)
Factors influencing liver disease progression in chronic hepatitis B (2006) (23)
Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. (2012) (22)
Serum—ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites (1992) (22)
Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) (2005) (22)
Absence of precore stop mutant in chronic dual (B and C) and triple (B, C, and D) hepatitis virus infection. (1994) (22)
424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2004) (22)
The prevalence and prognostic significance of spontaneous bacterial peritonitis in severe acute hepatitis with ascites (1992) (21)
Hepatitis B virus genotype B is associated with better response to thymosin α1 therapy than genotype C (2006) (21)
Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study (2009) (21)
Seroepidemiology of human T lymphotropic viruses and hepatitis viruses among prostitutes in Taiwan. (1988) (21)
Original articleT-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection☆ (1995) (21)
Spontaneous regression of hepatocellular carcinoma. (1992) (21)
Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. (2015) (20)
Vitamin A, Vitamin E or beta-carotene status and hepatitis B-related hepatocellular carcinoma. (1993) (20)
Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901 (2008) (20)
Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts. (1996) (20)
Simultaneous acute infections with hepatitis non-A, non-B, and B viruses (1982) (20)
Current Trend in Antiviral Therapy for Chronic Hepatitis B (2022) (20)
Intravenous cholescintigraphy using Tc-99m-labeled agents in the diagnosis of choledochal cyst. (1982) (19)
220 Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial (2003) (19)
α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare. (2016) (19)
Abnormal pre-drainage serum creatinine as a prognostic indicator in acute cholangitis. (1992) (19)
Comparative Studies on Expression of α-Smooth Muscle Actin in Hepatic Stellate Cells in Chronic Hepatitis B and C (2008) (19)
Polyadenylation of the mRNA of hepatitis delta virus is dependent on the structure of the nascent RNA and regulated by the small or large delta antigen. (1994) (19)
Ultrasonically-guided needle aspiration with preparation of cell blocks in the diagnosis of liver tumors. (1994) (19)
Hepatitis B virus e antigen and primary hepatocellular carcinoma. (1991) (19)
A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients (1996) (19)
911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS (2009) (18)
The role of delta superinfection in acute exacerbations of chronic type B hepatitis. (2008) (18)
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. (2018) (18)
Treatment of chronic hepatitis B: A need for consensus (1999) (18)
Viral Superinfection in Previously Unrecognized Chronic Carriers of Hepatitis B Virus with Superimposed Acute Fulminant versus Nonfulminant Hepatitis (1999) (18)
The aetiology of acute hepatitis in Taiwan: Acute hepatitis superimposed on HBsAg carrier state as the main aetiology of acute hepatitis in areas with high HBsAg carrier rate (1988) (17)
Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis (2001) (17)
Detection of hepatitis B and C viruses in liver tissue with hepatocellular carcinoma. (1994) (17)
Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses (2022) (17)
Epidemiological characteristics, risk factors, and clinical manifestations of acute non‐A–E hepatitis (2001) (17)
Chronic hepatitis with nonspecific histological changes. Is it a distinct variant of chronic hepatitis? (2008) (17)
Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area (2006) (17)
Quantitative assessment of hepatitis C virus RNA by polymerase chain reaction and a digoxigenin detection system: comparison with branched DNA assay. (1997) (17)
Transcatheter hepatic arterial embolization in the treatment of hepatocellular carcinoma. (1990) (16)
The Window Period Between Hepatitis B e Antigen and Antibody in Chronic Type B Hepatitis (1984) (16)
A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma. (1994) (16)
Viral Load, Genotypes, and Mutants in Hepatitis B Virus-Related Hepatocellular Carcinoma: Special Emphasis on Patients with Early Hepatocellular Carcinoma (2011) (16)
Great and rapid HBsAg decline in patients with on‐treatment hepatitis flare in early phase of potent antiviral therapy (2018) (15)
Towards consensus on the control of chronic hepatitis B and hepatitis C in the Asia–Pacific region (2000) (15)
[Comparison of Olympus GIF-P2 and GIF-K panendoscopy]. (1979) (15)
Pharmacotherapeutic options for hepatitis B (2016) (15)
Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients (2019) (15)
Thymalfasin for the treatment of chronic hepatitis B (2004) (15)
Ticlopidine-induced cholestatic hepatitis with anti-nuclear antibody in serum. (2000) (15)
Hepatitis delta virus infection in Taiwan. (1987) (14)
Natural course of patients with chronic type B hepatitis following acute hepatitis delta virus superinfection. (2008) (14)
Genetic alternations of p73 are infrequent but may occur in early stage hepatocellular carcinoma. (2000) (14)
A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment. (2004) (14)
Early detection of anti-HCc antibody in acute hepatitis C virus (HCV) by western blot (immunoblot) using a recombinant HCV core protein fragment (1994) (14)
Low prevalences of HBV and HCV infection in patients with primary biliary cirrhosis in Taiwan: A case control study (1993) (14)
Thyroxine-binding globulin in patients with chronic hepatitis B virus infection: different implications in hepatitis and hepatocellular carcinoma. (1990) (13)
Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B (2014) (13)
Acute hepatitis delta virus superinfection in patients with liver cirrhosis. (1990) (13)
Hepatocellular carcinoma presenting as acute spontaneous haemothorax (1990) (13)
Viral Hepatitis in Taiwan: Status in the 1990s (1994) (13)
Re‐treatment for severe hepatitis flare in HBeAg‐negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics (2019) (13)
Treatment of chronic type B hepatitis in Southeast Asia. (1988) (13)
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites]. (1982) (12)
Radionuclide venography in Budd-Chiari syndrome with intrahepatic vena-caval obstruction. (1985) (12)
C ASE R EPORT: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B (1999) (12)
[A clinical study on acute hepatitis A---with special reference to its occurrence in HBsAg carriers]. (1983) (12)
Short-Term Lamivudine Therapy in Patients with Chronic Hepatitis B (2003) (11)
Peripheral T-cell subsets in asymptomatic hepatitis B-virus carriers. (1986) (11)
Serum levels of interferon-α and-γ in acute and chronic hepatitis B virus infection (1995) (11)
Intrahepatic expression of HBcAg in chronic HBV hepatitis: Lessons from molecular biology (1990) (11)
Modulation of tumor necrosis factor receptors 1 and 2 in chronic hepatitis B and C: the differences and implications in pathogenesis. (2001) (11)
Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C (1998) (11)
Etiology and Pathogenesis of Hepatocellular Carcinoma (1995) (11)
Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. (2010) (11)
Liver biopsy in asymptomatic carriers of HBsAg. (1979) (11)
Acute delta superinfection in a previously unrecognised HBsAg carrier with transient loss of HBsAg simulating acute non-A, non-B hepatitis. (1988) (11)
DNA measurements in chronic hepatitis, cirrhosis and hepatocellular carcinoma. (2008) (11)
SOX2 promoter hypermethylation in non-smoking Taiwanese adults residing in air pollution areas (2019) (10)
Biliary alkaline phosphatase measured by mini-column chromatography on DEAE-cellulose: application to detection of hepatobiliary diseases. (1989) (10)
YAG laser endoscopic treatment of an esophageal and sigmoid stricture after end-to-end anastomosis stapling. (1984) (10)
Peripheral T-cell subsets in chronic type B hepatitis: correlation with biochemical and histological activities and hepatitis B e antigen/antibody status. (1984) (10)
Characterization of nuclear localization of a hepatitis B virus precore protein derivative P22 (2005) (10)
Distinct composition of viral quasispecies between ascites and serum samples from patients with late stage chronic hepatitis C. (1996) (10)
Acute leukaemia in chronic hepatitis B patients with lamivudine therapy (2004) (10)
Intrahepatic expression of pre-S1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta virus superinfection. (1992) (10)
Hepatocyte hepatitis B surface antigen. Diagnostic evaluation of patients with clinically acute hepatitis B surface antigen-positive hepatitis. (1985) (10)
Serum levels of interferon-alpha and -gamma in acute and chronic hepatitis B virus infection. (1995) (10)
O113 COMBINATION THERAPY WITH PEGINTERFERON ALFA-2a AND A NUCLEOS(T)IDE ANALOGUE FOR HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (2014) (10)
Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year (2006) (10)
Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B (2013) (10)
Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response (1999) (10)
Case report: spontaneous peritonitis caused by Candida albicans. (1999) (9)
Different implications of stigmata of recent hemorrhage in gastric and duodenal ulcers (1988) (9)
Polymorphisms in XRCC 1 and Glutathione S-Transferase Genes and Hepatitis B – Related Hepatocellular Carcinoma (2003) (9)
Outpatient liver biopsy. (1978) (9)
Etiology of fulminant viral hepatitis (1985) (9)
[Chronic hepatitis in Taiwan. II. A clinical and laboratory study (author's transl)]. (1981) (9)
Immunopathology on Hepatocyte Expression of HBV Surface, Core, and x Antigens in Chronic Hepatitis B: Clinical and Virological Correlation (2010) (9)
51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients (2006) (9)
49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB) (2006) (9)
Comparison of intravenous radionuclide cholescintigraphy and endoscopic retrograde cholangiography in the diagnosis of intrahepatic gall-stones. (1981) (8)
Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies (2021) (8)
521 HEPATOCELLULAR CARCINOMA DEVELOPMENT IN HBe-NEGATIVE HEPATITIS B CIRRHOTIC PATIENTS WITH ENTECAVIR TREATMENT (2013) (8)
The clinical significance of gall-bladder non-visualization in cholescintigraphy of patients with choledochal cysts (1996) (8)
Treatment of chronic hepatitis B virus infection: who, when, what for and how (2000) (8)
[A clinicopathological study in primary biliary cirrhosis]. (1992) (8)
Guillain‐Barré syndrome associated with acute delta hepatitis virus superinfection (1989) (8)
Diagnosis of acute type B hepatitis by a solid phase u-antibody capture radioimmunoassay for IgM class antibody to hepatitis B core antigen: a diagnostic proposal based on a prospective study. (2008) (8)
Quantitative assessment of serum hepatitis B virus DNA: comparison between two different methods (1997) (8)
Pathological rupture of spleen in hepatitis B virus-related cirrhosis. (1993) (8)
Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. (2002) (8)
[Drug therapy in patients with chronic type B hepatitis]. (1995) (8)
Immune Tolerance Phase of Chronic Hepatitis B. (2017) (8)
Replication of hepatitis C virus in ascitic mononuclear cells with development of distinct viral quasispecies. (1999) (8)
Hepatitis delta virus infection in southern Taiwan. (1989) (7)
Original articleCellular immune responses in patients with dual infection of hepatitis B and C viruses: Dominant role of hepatitis C virus☆ (1995) (7)
Association of ADH1B polymorphism and alcohol consumption with increased risk of intracerebral hemorrhagic stroke (2021) (7)
Responses are durable for up to 5 years after completion of peginterferon alfa‐2a treatment in hepatitis B e antigen‐positive patients (2018) (7)
Prognosis of immune-tolerant phase chronic hepatitis B (2017) (7)
Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection (2020) (7)
1012 TELBIVUDINE-INDUCED HBEAG SEROCONVERSION IN CHRONIC HEPATITIS B (CHB) IS DURABLE DURING 2 YEARS OFF-TREATMENT FOLLOW-UP (2010) (7)
The incidence of fulminant hepatic failure in acute viral hepatitis in Taiwan: Increased risk in patients with pre-existing HBsAg carrier state (1990) (7)
Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients. (2018) (7)
Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis (2021) (7)
Alpha fetoprotein and hepatic regeneration. (1979) (7)
Serum levels of soluble Tac peptide in acute and chronic hepatitis B virus infection. (1989) (7)
Intrahepatic expression of hepatitis B core and surface antigens in chronic hepatitis delta-virus infection. (1992) (7)
Why most patients with hepatitis delta virus infection are seronegative for hepatitis B e antigen. A prospective controlled study. (1991) (7)
HBsAg seroclearance in Asian patients: too high and too bad in Hong Kong. (2009) (7)
Primary calcified gastrinoma of the liver. (2001) (7)
C ASE R EPORT: Spontaneous peritonitis caused by Candida albicans (1999) (7)
[Histocompatibility profile of hepatoma in Taiwan]. (1982) (7)
Alteration of the subcellular localization of hepatitis B virus core protein by large but not small surface proteins. (1994) (6)
[Hematological abnormalities in acute viral hepatitis and acute hepatitis in HBsAg carrier]. (1991) (6)
Intrahepatic expression of HBcAg and delta antigen in anti‐HBe positive HBsAg carriers with acute exacerbation or chronic active liver disease (1990) (6)
Hepatitis C virus infection in patients with chronic liver diseases in an endemic area for hepatitis B virus infection (1991) (6)
Natural History of Hepatitis B Virus Infection (2016) (6)
Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation” (2022) (6)
[A clinical study on acute pancreatitis]. (1982) (6)
Interim Results of a Double-blind, Randomized Phase 2 Study of the Safety of Tenofovir Disoproxil Fumarate, Emtricitabine plus Tenofovir Disoproxil Fumarate ,and Entecavir in the treatment of chronic hepatitis B subjects with Decompensated liver disease (2009) (6)
Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B. (1999) (5)
High serum alkaline phosphatase in septemic infection. (1980) (5)
Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases (2005) (5)
Endogenous septic endophthalmitis in severe acute hepatitis with septicemia. (1991) (5)
Alpha-fetoprotein in liver diseases in Taiwan. (1974) (5)
Spontaneous HBsAg seroclearance confers excellent prognosis except in patients with cirrhosis (2004) (5)
[Hepatitis B antigen and alpha-fetoprotein in hepatoma in Taiwan]. (1973) (5)
Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. (2021) (5)
A survey and follow-up study of anicteric hepatitis, other asymptomatic liver diseases and hepatitis B surface antigen carriers. (1979) (5)
HBeAg/ANTI-HBe AND ALPHA-FETOPROTEIN LEVELS IN PRIMARY HEPATOCELLULAR CARCINOMA (1982) (5)
Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte responses via peptide-MHC tetrameric complexes assay (2001) (5)
Management of chronic hepatitis B: an evolving issue (2006) (5)
Chronic hepatitis B guidelines: East versus West (2002) (5)
Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B. (2020) (5)
Current treatment of chronic HBV infection: An Asian-Pacific perspective (2009) (5)
Identification of a novel pre‐S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen (2003) (5)
[Studies on chronic hepatitis in Taiwan. I. Types and etiology]. (1981) (5)
Suppression of hepatitis delta virus by concurrent hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. (1993) (5)
Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China (2016) (5)
Taiwan's health-care system and administration are independent of China (2019) (4)
Interaction of Osteoarthritis and BMI on Leptin Promoter Methylation in Taiwanese Adults (2019) (4)
A single serine mutation on the nuclear localization signal of hepatitis B virus core protein abolishes the inhibition of nuclear transport by surface proteins. (1995) (4)
Chronic hepatitis caused by the hepatitis a virus (1990) (4)
Asian Pacific Association for Study of the Liver (APASL) (2003) (4)
Responding to the progress in hepatology: beyond the boundaries (2007) (4)
[The etiology of adult acute viral hepatitis in Taiwan]. (1982) (4)
Role of N-acetyltransferase polymorphisms in hepatitis B-related hepatocellular carcinoma: impact on risk of smoking (2000) (4)
Indocyanine green clearance test in non-cirrhotic hepatitis patients: a comparison and analysis between conventional blood sampling method and Finger Piece Monitoring method. (1999) (4)
Hepatocyte expression of HBcAg and serum HBeAg in hepatitis B: comparison of polyclonal and monoclonal antibodies during a trial of interferon. (1991) (4)
Olone modulates the therapeutic effect of interferon to eliminate preferentially the hepatitis B virus precore stop mutant. (2000) (3)
Long-term cognitive and multimodal imaging outcomes after carotid artery stenting vs intensive medication alone for severe asymptomatic carotid stenosis. (2021) (3)
Long-term immunoprophylaxis for hepatitis B virus reinfection after liver transplantation. (1996) (3)
Epidemiological characteristics and risk factors of hepatocellular carcinoma : Molecular biology, pathogenesis and clinics (1997) (3)
Increased incidence of HBsAg seroclearance in HBeAg negative chronic hepatitis B patients discontinued Nuc therapy comparing to natural course-a propensity score matched study (2018) (3)
Viral load in hepatitis B e antigen–negative carriers with normal aminotransferase level (2007) (3)
1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION (2010) (3)
No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B (2018) (3)
Albumin gradient and portal vein velocity in severe viral hepatitis patients complicated with ascites. (2000) (3)
[Clinical study of primary intrahepatic stones]. (1983) (3)
Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte responses via peptide-MHC tetrameric complexes assay (2004) (3)
The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B (2020) (3)
Overt acute hepatitis B is more severe in female patients (2017) (3)
Hepatocellular carcinoma incidence is reduced in cirrhotic chronic hepatitis B patients with HBsAg seroclearance comparing to those with viral suppression (2022) (3)
Taiwan’s contribution to clinical research in gastroenterology and hepatology (2004) (3)
Role of antiviral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma (2004) (3)
Long-term outcomes after cessation of antiviral therapy in HBeAg negative patients (2022) (2)
Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study (2022) (2)
Intrahepatic stones in association with cholangiocarcinoma (1988) (2)
Serodiagnosis of acute B hepatitis: comparison between a competitive binding radioimmunoassay and an enzyme linked immunosorbent assay for IgM antibody to hepatitis B core antigen. (1985) (2)
Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results (1990) (2)
Advances in Brief Aberrant Transcripts of the Cyclin-dependent Kinase-associated Protein Phosphatase in Hepatocellular Carcinoma 1 (2000) (2)
Hepatitis B flare: the good, the bad and the ugly (2022) (2)
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma (2016) (2)
Letter: lessons from the ‘real‐world’ entecavir therapy in chronic hepatitis B patients (2016) (2)
The role of off-therapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients. (2022) (2)
[A clinical and prognostic study of non-A, non-B hepatitis]. (1983) (2)
Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B (2019) (2)
P1045 ESTIMATING THE PROBABILITY OF RESPONSE TO PEG-INTERFERON THERAPY IN HBeAg-POSITIVE CHRONIC HEPATITIS B: THE EPIC-B STUDY (2014) (2)
Long-term outcome of entecavir therapy in chronic hepatitis B with cirrhosis. (2020) (2)
906 EFFICACY OF 3 YEARS OF TELBIVUDINE TREATMENT FOR PATIENTS WITH GENOTYPE B/C CHRONIC HEPATITIS B (CHB) (2009) (2)
A Prospective Study on the Prognostic Significance of Bridging Hepatic Necrosis in Acute Viral Hepatitis (1984) (2)
P.104 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2006) (2)
Prevalence and significance of intrahepatic hepatitis delta virus antigen expression in HBeAg-negative patients with chronic type-B hepatitis in Taiwan (1989) (2)
320 Long-Term Histologic Improvement with Entecavir (ETV) Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs (2009) (2)
[Fulminating viral hepatitis--a clinical study]. (1986) (2)
The Significance of Nonvisualization of Extrahepatic Bile Duct in Intravenous Radionuclide Cholescintigraphy with Special Reference to Acute Suppurative Cholangitis (1984) (2)
Liver transplantation for hepatic malignancy. (1998) (2)
CASE REPORT: Primary Calcified Gastrinoma of the Liver (2001) (2)
Gender Impacts on the Disease Severity of Overt Acute Hepatitis A: Different from Overt Acute Hepatitis B (2018) (2)
Liver transplantation in Chinese patients with chronic hepatitis B. (2000) (2)
HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study (2016) (2)
Sequential Changes of Hepatitis C Virus Antibody Profiles during Treatment of Chronic Hepatitis C of Genotype 1b: Pretreatment Antibody Response to E2/NS1 Correlated Sustained Response (2004) (2)
Serum HBsAg kinetics in clinical prediction. (2017) (2)
Disputing issues in the paradigm change to finite antiviral therapy in HBeAg negative patients. (2021) (2)
[Endoscopic retrograde cholangiopancreatography in gastrectomized patients (author's transl)]. (1979) (1)
Puriﬁcation and Characterization of a Naturally Processed Hepatitis B Virus Peptide Recognized by CD8 (cid:49) Cytotoxic T Lymphocytes (1996) (1)
Non-surgical treatment of hepatocellular carcinoma : Molecular biology, pathogenesis and clinics (1997) (1)
Dual infection with HBV and HCV in hepatocellular carcinoma (1997) (1)
Natural Course of Chronic Hepatitis B Virus Infection (2012) (1)
Nomograms for risk of heptocellular carcinoma in patients with chronic heaptitis B virus infection (2010) (1)
[Serum level of N-terminal peptide of procollagen type III in chronic liver disease]. (1987) (1)
Early Detection of Hepatacellular Carcinoma in Patients With Chronic Type B Hepatitis (1986) (1)
Genetic Variation in FCER1A Gene Predicts Sustained HBsAg Clearance in East-Asian Patients Treated with Pegylated Interferon Alfa-2a (40kd): The “Peg-Be-Yond” Study (2016) (1)
Clinical and pathologic features of hepatitis B virus reinfection after liver transplantation. (1994) (1)
[Nd-YAG laser endoscopy for the treatment of upper gastrointestinal bleeding]. (1983) (1)
[Malignant hemangioendothelioma of the liver --case report and review of literature (author's transl)]. (1978) (1)
[Liver biochemical tests in paraquat intoxication]. (1988) (1)
Methylation at cg05575921 of a smoking-related gene (AHRR) in non-smoking Taiwanese adults residing in areas with different PM2.5 concentrations (2019) (1)
[The prognostic value of early endoscopy in peptic ulcers bleeding]. (1985) (1)
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase” (2023) (1)
[Choledochal cyst: findings of intravenous radionuclide cholescintigraphy, sonography, and endoscopic retrograde cholangiography]. (1989) (1)
[A retrospective study on acute post-transfusion hepatitis (author's transl)]. (1980) (1)
Long-term entecavir therapy improves fibrosis/cirrhosis and results in continued histologic improvement in CHB (2009) (1)
[Small intestinal diseases complicated by malabsorption syndromes]. (1986) (1)
The influence of liver function tests on intravenous radionuclide cholescintigraphy. (1980) (1)
Original contributionClinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers (1998) (1)
Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies (2022) (1)
[Changes in thyroid hormone concentration in liver disease]. (1989) (1)
Stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. (2020) (1)
464 ATTENUATION OF HEPATIC INFLAMMATION BY ADMINISTRATING CD55 TO A MURINE MODEL OF STEATOHEPATITIS (2008) (1)
Peritoneoscopic guided aspiration cytology in the diagnosis of liver malignancy. (1981) (1)
Abnormal transcripts for caspase-activated DNase in human hepatoma cells (2002) (1)
AB032. S7-3. Introduction of Taiwan Liver Cancer Network (2019) (1)
Purification and Characterization of a Naturally Processed Hepatitis B Virus Peptide Recognized by CD 8 1 Cytotoxic T Lymphocytes (2013) (1)
P-54 High prevalence of thyroid auto-antibodies in patients with chronic hepatitis C (1995) (1)
A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study (2022) (1)
[Chronic hepatitis in Taiwan. III. Sex difference in chronic hepatitis]. (1982) (1)
747 Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B (2006) (1)
Reply to "letter to the editor"-combination therapy for chronic hepatitis B: The future and beyond. (2018) (1)
Long-term entecavir (ETV) therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg positive and negative chronic hepatitis B (CHB): results from studies ETV-022,-027 and-901 (2009) (1)
Prednisolone withdrawal followed by recombinant alfainterferon in chronic non-A, non-B hepatitis: An interim results of a randomized controlled trial (1991) (1)
48 Interferon therapy reduces cirrhosis and hepatocellular carcinoma in HBeAg positive chronic hepatitis B (2006) (1)
T-cell-mediated autologous hepatotoxicity in patients with chornic hepatitis C virus infection (1995) (1)
[Natural history of hepatitis B and D virus infections]. (1992) (1)
Role of the Ribozyme of Hepatitis Δ Virus on the Transcription After Polyadenylation (1994) (1)
Prognostic significance of HBeAg. (1980) (1)
Modulation of Tumor Necrosis Factor Receptors 1 and 2 in Chronic Hepatitis B and C: The Differences and Implications in Pathogenesis (2001) (1)
745 eGFR IMPROVEMENT IN CHRONIC HEPATITIS B PATIENTS WITH TELBIVUDINE TREATMENT IS INDEPENDENT OF ANTIVIRAL ACTIVITY (2013) (1)
[Hepatitis after halothane exposure (author's transl)]. (1978) (1)
Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy (2022) (1)
[The value of bile carcinoembryonic antigen in the differentiation of benign from malignant biliary obstruction]. (1985) (1)
Increased sister chromatid exchange frequency in peripheral lymphocytes of hepatocellular carcinoma patients (1993) (1)
Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection (2022) (1)
Towards a rational treatment strategy for chronic hepatitis B (2007) (1)
Management of older patients with immunotolerant chronic hepatitis B infection. (2022) (1)
Letter: nucleos(t)ide analogues are good, but not sufficient for hepatitis B virus clearance – author's reply (2016) (1)
Liver transplantation for a hepatitis B-related cirrhotic patient. (1993) (1)
Sex-related differences in cluster headache: A hospital-based study in Taiwan (2022) (1)
Role of the ribozyme of hepatitis delta virus on the transcription after polyadenylation. (1994) (1)
evel of Hepatitis B Virus DNA in Inactive Carriers With Persistently ormal Levels of Alanine Aminotransferase HIA – (0)
[Diagnostic value of ERC in gall bladder diseases (author's transl)]. (1981) (0)
[The clinical significance of amylase-creatinine clearance ratio (Cam/Ccr) in G-I disorders (author's transl)]. (1978) (0)
[Budd-Chiari syndrome--a clinical study on the obstruction of hepatic portion of inferior vena cava]. (1982) (0)
P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS (2014) (0)
Title Asian-Pacific consensus statement on the management ofchronic hepatitis B : a 2008 update (2008) (0)
361 HBSAG LEVELS PREDICT HBSAG SEROCLEARANCE IN 3 YEARS: A MATCHED CASE CONTROL STUDY (2011) (0)
The Journal of Gastroenterology and Hepatology, 10 years on (1996) (0)
Plenary sessions: oral presentations (2006) (0)
Contents Vol. 46, 2003 (2003) (0)
Quiz of the Month / Announcements (1991) (0)
P0610 : Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up (2015) (0)
Effects of Multiple Risk Factors for Hepatocellular Carcinoma on Formation of Aflatoxin -DNA (1996) (0)
[Gastric carcinoma in a young adult (author's transl)]. (1981) (0)
expression ofhepatitis B coreandE antigens in chronic typeBhepatitis (1992) (0)
[Serum alkaline phosphatase in bacteremia (author's transl)]. (1982) (0)
Overt Acute Hepatitis B Deteriorates in Females: Destructive Immunity With an Exaggerated Interleukin-17 Pathway (2021) (0)
649 A PROSPECTIVE COHORT STUDY OF MULTIPLE RISK FACTORS AND AGE AT ONSET OF HEPATOCELLULAR CARCINOMA IN HEPATITIS B VIRUS CARRIERS (2013) (0)
1047 Is abrupt increase in corticosteroids in patients with asthma or copd linked to specific types of lung cancer (2015) (0)
Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study (2022) (0)
Distinct relapse patterns between HBeAg-negative patients stopping tenofovir and entecavir. (2022) (0)
Immune Responses and Hepatitis B Surface Antigen Loss After Cessation of Direct Antiviral Therapy in Hepatitis B e Antigen-Negative Patients. (2018) (0)
[321] ACTIVATION OF COMPLEMENT AND COAGULATION PATHWAYS IS THE POTENTIAL CULPRIT CAUSING INFLAMMATION AND FIBROSIS IN HEPATIC STEATOSIS: A STUDY IN CONDITIONALLY HCV CORE TRANSGENIC MICE (2007) (0)
Sucralfate in the Short-Term Treatment of Duodenal Ulcer: A Double-Blind Clinical Trial (1984) (0)
Analysis on the status of hepatitis B virus DNA in peripheral blood mononuclear cells of chronic hepatitis B patients (1993) (0)
Natural history of chronic hepatitis B virus infection : An immunopathological study : Molecular biology, pathogenesis and clinics (1997) (0)
Chronic hepatitis after overt acute non-A, non-B post-transfusion hepatitis in Taiwan. (1982) (0)
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure (2023) (0)
The Role of HBsAg Quantification in the Natural Course of HBV Infection in Asia (2013) (0)
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. (2004) (0)
Hepatic Adenoma: Report of a Case (1994) (0)
Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection. (2022) (0)
[Ischemic hepatitis]. (1982) (0)
P.375 Sequence variation in the enhancer 2/basal core promoter/precore region of hepatitis B virus and subsequent risk for hepatocellular carcinoma (2006) (0)
Association of ADH1B polymorphism and alcohol consumption with increased risk of intracerebral hemorrhagic stroke (2021) (0)
Case report: Unusual viral evolutions following antiviral therapies in a patient with concurrent hepatitis B virus and hepatitis C virus infection (2023) (0)
[e-Antigen and antibody in HBsAg carriers and liver diseases in Taiwan (author's transl)]. (1979) (0)
[Histocompatibility profile of hepatitis in Taiwan (author's transl)]. (1982) (0)
[Splenic abscess--a case report (author's transl)]. (1979) (0)
Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study (2020) (0)
[Diagnostic value of Tc-99m-pyridoxylideneglutamate cholescintigraphy in gall bladder diseases (author's transl)]. (1979) (0)
[e-antigen and antibody in acute viral hepatitis (author's transl)]. (1979) (0)
Evoked potentials in liver diseases : Molecular biology, pathogenesis and clinics (1997) (0)
Proceedings of the International Symposium on Hepatology, Taipei, Taiwan (1997) (0)
[Complications of ERCP (author's transl)]. (1981) (0)
[The hepatic manifestation in bacteremia (author's transl)]. (1980) (0)
Radionudide Venographyin Budd-ChiariSyndrome with IntrahepaticVena-Caval Obstruction (2006) (0)
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy. (2021) (0)
Immunotolerant HBeAg Positive Patients: To Treat or Not to Treat (2014) (0)
Subject Index Vol. 46, 2003 (2003) (0)
AUTHOR INDEX (2006) (0)
Remote and short-term prediction of spontaneous HBsAg seroclearance. (2023) (0)
F5-3 Treatment of hepatitis in Asia and future perspectives (1995) (0)
469 GENETIC MAPPING QUANTITATIVE TRAIT LOCI FOR HOST CONTROL OF HBV VIRAL LOAD IN THE HLA REGION AMONG FAMILIES OF HEPATOCELLULAR CARCINOMA (2012) (0)
Acutedelta superinfection inapreviously unrecognised HBsAgcarrier withtransient loss of HBsAgsimulating acute non-A, non-Bhepatitis (1988) (0)
[Inflammatory complications of pancreatitis (author's transl)]. (1980) (0)
ALDH7A1 rs12514417 polymorphism may increase ischemic stroke risk in alcohol-exposed individuals (2022) (0)
Reply (1984) (0)
33 Regulatory T cells contributed partially to the defective functions of virus-specific exhausted CD8+T cells in patients with chronic hepatitis B virus infection (2006) (0)
Short title : Sex difference in acute hepatitis B Contact information (2017) (0)
Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients (2019) (0)
[320] EVIDENCE FOR APOPTOSIS-MEDIATED INVOLVEMENT OF HEPATIC STELLATE CELLS IN THE PATHOGENESIS OF HCV-RELATED LIVER FIBROSIS (2007) (0)
Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis (2021) (0)
Reactivation of Hepatitis C Virus Superinfection in a Patient Seropositive for Hepatitis B e Antigen (2001) (0)
[Studies of hepatitis markers in hemodialysis patients in Taiwan]. (1986) (0)
Management of Drug‐Resistant Mutants (2007) (0)
Steroids, Bridging necrosis in hepatitis. (1981) (0)
Response to Wiwanitkit (2010) (0)
Preparation of Polyacrylonitrile-based Immobilized Metal-Ion Affinity Membrane for Protein Adsorption (2012) (0)
[A review of 1,000 percutaneous needle biopsies of the liver (author's transl)]. (1981) (0)
KETOCONAZOLE-INDUCED HEPATOTOXICITY. AUTHORS' REPLY (1997) (0)
M1897 Risk and Predictors of Mortality or Hepatocellular Carcinoma Among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients With Evidence of Hepatic Decompensation (2010) (0)
378 Liver Disease Progression in Chronic Hepatitis B Infected Persons with Normal Serum Alanine Amino Transferase Level: Update from the R.E.V.E.A.L.-HBV Study (2008) (0)
Clinicopathological response of HBsAg-positive chronic active hepatitis to adenine arabinoside: Lack of correlation with DNA polymerase response (1984) (0)
AFP in chronic hepatitis B virus infection (1989) (0)
[Double-blind therapeutic trial of active duodenal ulcer disease with "Cimetidine" (author's transl)]. (1979) (0)
P1051 EVALUATION OF ESTIMATED GLOMERULAR FILTRATION RATE DURING CONTINUOUS 4-YEAR TREATMENT WITH TELBIVUDINE IN PATIENTS WITH BRIDGING FIBROSIS/CIRRHOSIS (2014) (0)
Perspectives on current controversial issues in the management of chronic HBV infection (2022) (0)
P655 GENDER DIFFERENCE IN THE EFFECT OF HEPATITIS B VIRUS GENOTYPE ON DISEASE PROGRESSION (2014) (0)
[Primary carcinoma of the gallbladder]. (1983) (0)
Reply: (2009) (0)
P0662 : 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials (2015) (0)
Reply to Letter to the Editor: Retreatment Decision for Hepatitis B Flare (2020) (0)
Diagnosis and onset of acute hepatitis delta virus infection (1990) (0)
Preoperative Evaluation of Gastric Cancer by Laparoscopy: The Significance of Serosal Invasion (1990) (0)
Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B (2019) (0)
754 PATTERNS OF HBV GENOTYPE C-SPECIFIC SEQUENCE VARIATION AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (2012) (0)
[Ultrasonographic patterns of primary carcinoma of the gallbladder]. (1983) (0)
Longer consolidation duration is required to reduce 1-year clinical relapse rate after stopping tenofovir in HBeAg negative CHB patients (2020) (0)
[Endoscopic Nd-YAG laser treatment of gastrointestinal polyps]. (1983) (0)
FRI-178-The clinical significance and predictors for precipitous HBsAg decline in off entecavir therapy HBeAg negative patients (2019) (0)
[Needle biopsy of the liver in outpatients (author's transl)]. (1978) (0)
SOX2 promoter hypermethylation in non-smoking Taiwanese adults residing in air pollution areas (2019) (0)
644 LIVER DISEASE PROGRESSION IN CHRONIC HEPATITIS B INFECTED PERSONS WITH NORMAL SERUM ALANINE AMINO TRANSFERASE LEVEL: UPDATE FROM THE R.E.V.E.A.L.-HBV STUDY (2008) (0)
Towards HBV Eradication: Future Perspective (2016) (0)
Predictors for clinical relapse within 2 year off-ETV therapy in HBeAg negative chronic hepatitis B patients (2017) (0)
Organization of The Third International Symposium on Viral Hepatitis and Hepatocellular Carcinoma (1993) (0)

This paper list is powered by the following services:

Other Resources About Liaw Yun-fan

en.wikipedia.org

What Schools Are Affiliated With Liaw Yun-fan?

Liaw Yun-fan is affiliated with the following schools:

Liaw Yun-fan's Academic­Influence.com Rankings